Tag: Aptevo

Aptevo Therapeutics Inc. (NASDAQ: APVO) is witnessing a substantial surge in share value during Wednesday’s pre-market session, rising 152.84% to $7.13. The stock’s sharp increase follows the company’s announcement of updated clinical-trial data.

Clinical Breakthrough

Aptevo Therapeutics shared data from its Phase 1b/2 RAINIER trial of mipletamig—a first-in-class CD123 x CD3 bispecific antibody being tested in combination with standard therapies venetoclax and azacitidine (ven/aza) in patients newly diagnosed with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.

Exceptional Remission Rates in Frontline AML

According to Aptevo, the combination therapy demonstrated remission in 85% of evaluable frontline AML patients across two studies. This rate notably surpasses outcomes seen in comparator trials such as the Viale A study, which evaluated ven/aza alone.

The first two patient cohorts showed encouragingly no signs of cytokine release syndrome (CRS), a common and severe adverse effect in many immunotherapies. Nearing full enrollment is Cohort 3, which is evaluating the greatest dosage level to yet.

Strategic Innovation Behind Mipletamig

The high efficacy and favorable safety data are credited to Aptevo’s proprietary CD3 engineering platform. Mipletamig uniquely utilizes the CRIS-7 binding domain, a strategic design intended to reduce cytokine-driven toxicity while maintaining potent anti-cancer activity.

This engineering approach not only underpins mipletamig’s current success but is also expected to strengthen future candidates in Aptevo’s pipeline, such as its preclinical prostate cancer therapy, APVO442.

Redefining AML Therapy for Unfit Patients

AML is a particularly aggressive blood cancer, with limited options and generally poor outcomes for elderly or medically unfit patients. Aptevo’s findings suggest that mipletamig may offer a new, more effective, and better-tolerated frontline therapy.

With 85% remission achieved—three of which were in patients with high-risk genetic profiles—Aptevo (APVO) positions mipletamig as a promising candidate to redefine treatment paradigms and elevate standards of care in a historically underserved population.

Aptevo Therapeutics Inc. (NASDAQ: APVO) shares are on a remarkable surge of 44.98% as of the last check today, reaching $2.01. This sharp increase in APVO stock follows a pivotal equity offering move by the biotechnology company, reinforcing investor confidence in its ongoing strategic initiatives.

Registered Direct Offering

Definitive securities purchase agreements for the issue of 1,764,710 shares of Aptevo Therapeutics’ common stock in a registered direct offering have been concluded. Concurrently, APVO has issued warrants to purchase up to 3,529,420 additional shares in a private placement. The total purchase price for each share and associated warrant is fixed at $1.19.

The warrants will be exercisable after shareholder approval and will be valid for five years after the initial exercise date. They have an exercise price of $1.19 per share. With the fulfillment of standard closing conditions, the offering is expected to close on or around April 4, 2025.

Before subtracting placement agency fees and related offering expenses, Aptevo expects to make around $2.1 million in gross proceeds. The money will go toward working capital, basic business needs, and the ongoing clinical development of its pharmaceutical prospects.

Positive Clinical Advancements

In a significant clinical advancement, Aptevo Therapeutics recently reported that two additional frontline acute myeloid leukemia (AML) patients have achieved remission within 30 days of treatment in its RAINIER dose optimization trial. The study evaluates the effectiveness of mipletamig in combination with the standard of care for patients unfit for intensive chemotherapy.

The latest data reinforces the promising results from Cohort 1 and the prior dose expansion trial, where all frontline patients attained remission. With these interim findings, mipletamig has demonstrated a compelling overall remission rate of 90% among frontline patients.

Future Prospects

Aptevo Therapeutics continues to see very positive remission rates in Cohort 2 of the RAINIER study, which has now crossed the halfway point. These findings highlight the potential benefits of mipletamig for AML patients who would ordinarily require venetoclax plus azacitidine as the conventional treatment but are not eligible for intense chemotherapy.

Aptevo is still committed to proving the effectiveness of mipletamig’s distinct mode of action in combination treatment. This strategy supports APVO’s efforts to develop cutting-edge treatments for AML and shows promise, especially for older patients with few therapy alternatives.